This session will feature world-class Alzheimer's researchers discussing recent breakthrough advances in developing predictive diagnostics for Alzheimer's Disease. Currently, there is no approved biomarker for diagnosing the disease, and physicians must rely on clinical observations. The successful development of a predictive, reliable and non-invasive diagnostic test would be of immense value not only to physicians and their patients, but also potentially to pharma companies with regard to
preclinical development and clinical trials design for Alzheimer's drugs in the pipeline.

• Provide expert insight on new and non-invasive for Alzheimer's diagnostics
• Discuss the significance to industry and patients of predictive diagnostics for Alzheimer's
• Discuss the relationship between Alzheimer's diagnostics and favorable treatment outcomes